Natalizumab in secondary progressive multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Defining secondary progressive multiple sclerosis.
A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis,...
متن کاملImpact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
BACKGROUND There is an unmet need for disease-modifying therapies to improve ambulatory function in disabled subjects with multiple sclerosis. OBJECTIVES Assess the effects of natalizumab on ambulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS). METHODS We retrospectively reviewed ambulatory function as...
متن کامل[Natalizumab treatment in multiple sclerosis].
Multiple sclerosis is a neurodegenerative and inflammatory immune disorder in the central nervous system (CNS). Most patients show relapse-remitting clinical course. Some disease modifying medications for preventing the relapses including natalizumab (NTZ) are approved in Japan. Natalizumab (NTZ), a monoclonal antibody against α4 integrin present on the surface of lymphocytes, inhibits the bind...
متن کاملNatalizumab for relapsing multiple sclerosis.
To the Editor: As Ropper pointed out in his editorial (March 2 issue),1 the three articles on the use of natalizumab in that issue of the Journal are pivotal, but his conclusion that natalizumab is “a potent treatment for multiple sclerosis” may be too sanguine. The similar entry criteria, treatment, and methods of analysis permit clinically useful conclusions to be drawn from the placebocontro...
متن کاملNatalizumab treatment for multiple sclerosis.
Correspondence: Maria Lucia Brito Ferreira; Rua Doutor José Maria, 841; 52040-000 Recife PE, Brasil; E-mail: [email protected] Conflict of interest: There is no conflict of interest to declare. Received 23 September 2014 Accepted 01 October 2014 The last five years had as benchmark the development of new drugs for treatment of multiple sclerosis. Its treatment has become complex because othe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Neurology
سال: 2018
ISSN: 1474-4422
DOI: 10.1016/s1474-4422(18)30108-x